351 related articles for article (PubMed ID: 30382803)
1. Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.
Conway F; Morosetti G; Camilli S; Martire FG; Sorrenti G; Piccione E; Zupi E; Exacoustos C
Gynecol Endocrinol; 2019 Mar; 35(3):207-210. PubMed ID: 30382803
[TBL] [Abstract][Full Text] [Related]
2. Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas.
Gracia M; Alcalà M; Ferreri J; Rius M; Ros C; Saco MA; Martínez-Zamora MÁ; Carmona F
J Minim Invasive Gynecol; 2018; 25(7):1274-1280. PubMed ID: 29626678
[TBL] [Abstract][Full Text] [Related]
3. Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound.
Baggio S; Pomini P; Galeone F; Presti F; Santi L; Raffaelli R; Franchi M
J Ultrasound Med; 2018 Sep; 37(9):2215-2223. PubMed ID: 29498074
[TBL] [Abstract][Full Text] [Related]
4. Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids.
Calderon L; Netter A; Grob-Vaillant A; Mancini J; Siles P; Vidal V; Agostini A
Reprod Biomed Online; 2021 Mar; 42(3):661-668. PubMed ID: 33349531
[TBL] [Abstract][Full Text] [Related]
5. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
6. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
7. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
8. Impact of pelvic magnetic resonance imaging findings in the indication of uterine artery embolization in the treatment of myoma.
Brito Pires NM; Godoi ET; Oliveira DC; Brandão SC; Abath CC; Pires P; Araujo Júnior E
Ginekol Pol; 2017; 88(3):129-133. PubMed ID: 28397200
[TBL] [Abstract][Full Text] [Related]
9. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study.
Czuczwar P; Wozniak S; Szkodziak P; Milart P; Wozniakowska E; Wrona W; Paszkowski T
Ultrasound Obstet Gynecol; 2015 Jun; 45(6):744-50. PubMed ID: 25251811
[TBL] [Abstract][Full Text] [Related]
10. Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.
Gracia M; Nonell R; Ros C; Rius M; Quintas L; Martínez-Zamora MÁ; Carmona F
Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():40-45. PubMed ID: 30468982
[TBL] [Abstract][Full Text] [Related]
11. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
12. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
[TBL] [Abstract][Full Text] [Related]
14. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
15. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Ciarmela P; Carrarelli P; Islam MS; Janjusevic M; Zupi E; Tosti C; Castellucci M; Petraglia F
Reprod Sci; 2014 Sep; 21(9):1120-5. PubMed ID: 25001022
[TBL] [Abstract][Full Text] [Related]
17. Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report.
Lo Monte G; Piva I; Graziano A; Engl B; Marci R
Eur Rev Med Pharmacol Sci; 2016; 20(2):202-7. PubMed ID: 26875885
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
19. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]